4D Molecular Therapeutics Initiates Phase 3 Trial of Gene Therapy Candidate for Diabetic Macular Edema
4D Molecular Therapeutics (FDMT) has begun enrolling patients in a Phase 3 clinical trial for its gene therapy candidate, 4D-150, aimed at treating diabetic macular edema (DME). This marks an important milestone as the company advances toward potential regulatory approval. The announcement comes amid mixed market sentiment; while the initiation of a late-stage trial is typically seen as positive news in biotech sectors, FDMT's stock has fallen nearly 10% to around $14.40. The Phase 3 study will evaluate the safety and efficacy of 4D-150, which uses proprietary AAV8 vector technology designed for long-term expression with a single dose. If successful, this could position FDMT as a key player in ophthalmic gene therapy. The trial is expected to provide critical data that may influence investor confidence and future valuation.
Tickers: $FDMT
Topics: 4D-150 biotech diabetic_macular_edema